State of the art

Individual differences in the neuropsychopathology of addiction

Olivier George, PhD; George F. Koob, PhD

Drug addiction or substance-use disorder is a chronically relapsing disorder that progresses through binge/intoxication, withdrawal/negative affect, *and* preoccupation/anticipation *stages. These stages represent diverse neurobiological mechanisms that are differentially involved in the transition from recreational to compulsive drug use and from positive to negative reinforcement. The progression from recreational to compulsive substance use is associated with downregulation of the brain reward systems and upregulation of the brain stress systems. Individual differences in the neurobiological systems that underlie the processing of reward, incentive salience, habits, stress, pain, and executive function may explain (i) the vulnerability to substance-use disorder; (ii) the diversity of emotional, motivational, and cognitive profiles of individuals with substance-use disorders; and (iii) heterogeneous responses to cognitive and pharmacological treatments. Characterization of the neuropsychological mechanisms that underlie individual differences in addiction-like behaviors is the key to understanding the mechanisms of addiction and development of personalized pharmacotherapy.*

Dialogues Clin Neurosci. 2017;19:217-228.

Psychopathological framework

Three stages of the addiction cycle: binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation

Drug addiction is a chronically relapsing disorder that is characterized by compulsion to seek and take the drug, loss of control in limiting drug intake, and emergence of a negative emotional state, reflecting a motivational withdrawal syndrome, when access to the drug is prevented.[1] Drug addiction includes three stages: *preoccupation/anticipation*, *binge/intoxication*, and *withdrawal/negative affect*. These three stages feed into each other to produce an addiction cycle. Each stage becomes more intense after each cycle, leading to the pathological state of addiction. These three stages reflect incentive salience/pathological habits, reward deficits/stress surfeit, and executive function deficits, respectively, which provide a powerful impetus for compulsive drug-seeking behavior that is associated with drug addiction. These domains of dysfunction corre-

Author affiliations: Department of Neuroscience, The Scripps Research Institute, La Jolla, California, USA (Olivier George); National Institute on Alcohol Abuse and Alcoholism, Rockville, Maryland, USA (George F. Koob)

Address for correspondence: Dr Olivier George, Department of Neuroscience, The Scripps Research Institute, 10550 North Torrey Pines Road, SP30-2400, La Jolla, CA 92037, USA
(email: ogeorge@scripps.edu)

spond to neuroadaptations that reflect allostatic changes in three key neurocircuits that mediate compulsive drug seeking: basal ganglia, extended amygdala, and prefrontal cortex, respectively (*Figure 1A*).[2] Allostasis in the context of addiction is the process by which the body responds to challenges to maintain apparent homeostasis through changes in brain reward and stress mechanisms.[3] The allostatic state represents a chronic deviation of reward set point that is mostly observed during abstinence and not observed when the individual is actively taking drug. Thus, the allostatic view extends counteradaptive theory by stating that not only does the *b-process* get larger with chronic drug use but the reward set point also progressively shifts

downward, thus creating an allostatic state (*Figure 1B*).[3,4] This model has been proposed to explain the persistent changes in motivation in drug-dependent individuals. We propose that the relative contribution of each of these three stages to drug use and drug addiction varies both between and within individuals across time.

## From positive to negative reinforcement

Another level of complexity that is added to these three stages is the fact that drug addiction includes a transition from impulsive to compulsive behaviors and from positive to negative reinforcement (*Figure 2*).[5,6] Impulsivity is

Figure 1. (Left) Three stages of the addiction cycle: *binge/intoxication*, *withdrawal/negative affect*, and *preoccupation/anticipation*. These three stages reflect incentive salience/pathological habits, reward deficits/stress surfeit, and executive function deficits, respectively, to provide a powerful impetus for compulsive drug-seeking behavior associated with drug addiction. These domains of dysfunction correspond to neuroadaptations that reflect allostatic changes in three key neurocircuits to mediate compulsive drug seeking: basal ganglia, extended amygdala, and prefrontal cortex, respectively. **(Top right)** The progression of alcohol dependence over time. The schematic illustrates the shift in underlying motivational mechanisms. From initial, positively reinforcing, pleasurable alcohol effects, the addictive process progresses over time to being maintained by negatively reinforcing relief from a negative emotional state. **(Bottom right)** The *a-process* represents a positive hedonic or positive mood state, and the *b-process* represents a negative hedonic or negative mood state. The affective stimulus (state) has been argued to be the sum of both the *a-process* and *b-process*. An individual who experiences a positive hedonic mood state from a drug of abuse with sufficient time between readministering the drug is hypothesized to retain the *a-process*. An appropriate counteradaptive opponent process (*b-process*) that balances the activational process (*a-process*) does not lead to an allostatic state. Changes in the affective stimulus (state) in an individual with repeated frequent drug use may represent a transition to an allostatic state in the brain reward systems and, by extrapolation, a transition to addiction. Notice that the apparent b-process never returns to the original homeostatic level before drug taking begins again, thus creating a progressively greater allostatic state in the brain reward system. The counteradaptive opponent-process (*b-process*) does not balance the activational process (*a-process*) but in fact shows residual hysteresis. Although these changes that are illustrated in the figure are exaggerated and condensed over time, the hypothesis is that even during post-detoxification (a period of protracted abstinence), the reward system still bears allostatic changes. The following definitions apply: *allostasis*, the process of achieving stability through change; *allostatic state*, a state of chronic deviation of the regulatory system from its normal (homeostatic) operating level; *allostatic load*, the cost to the brain and body of the deviation, accumulating over time, and reflecting in many cases pathological states and accumulation of damage.

Bottom right panel from reference 3: Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. *Neuropsychopharmacology*. 2001;24(2):97-129. Copyright © Nature Publishing Group, 2001. Top right panel from reference 4: Heilig M, Koob GF. A key role for corticotropin-releasing factor in alcohol dependence. *Trends Neurosci*. 2007;30(8):399-406. Copyright © Elsevier Applied Science Publishing, 2007

defined as "a predisposition toward rapid, unplanned reactions to internal or external stimuli without regard for the negative consequences of these reactions to [themselves] or others."[7] Compulsivity is defined as "perseverative, repetitive actions that are excessive and inappropriate."[8] Positive reinforcement is defined as the process by which presentation of a stimulus increases the probability of a response. Negative reinforcement is defined as the process by which removal of an aversive stimulus (or aversive state in the case of addiction) increases the probability of a response.[9] Impulsivity often dominates at the early stages of drug addiction through repeated binge/intoxication and positive reinforcement. Individuals seek and take the drug for its initial pleasurable and reinforcing effects without regard for the potential future negative consequences of using drugs. Compulsivity dominates at later stages of drug addiction through the emergence of negative emotional states in the *withdrawal/negative affect* stage and anticipation of obtaining the drug in the *preoccupation/anticipation* stage. Such compulsivity leads to the escalation of drug intake and perseverative drug use despite adverse consequences. The transition from positive to negative reinforcement

Figure 2. Schematic of the progression of drug addiction over time, illustrating the shift in underlying motivational mechanisms. From initial, positive reinforcing, pleasurable drug effects, the addictive process progresses over time to being maintained by negative-reinforcing relief from a negative emotional state. Adapted from reference 6: Koob GF. Theoretical frameworks and mechanistic aspects of alcohol addiction: alcohol addiction: alcohol addiction as a reward deficit disorder. In: Sommer WH, Spanagel R, eds. *Behavioral Neurobiology of Alcohol Addiction*. Berlin, Germany: Springer-Verlag; 2013:3-30. Current Topics in Behavioral Neuroscience; vol 13. © 2011, Springer-Verlag Berlin Heidelberg

reflects a change in the underlying psychological and neurobiological mechanisms of motivation (*Figure 2*). Motivation can be defined as a "tendency of the whole animal to produce organized activity."[10] The neural substrates for the two sources of reinforcement that play a key role in allostatic neuroadaptations derive from two key motivational systems that are required for survival: brain reward system and brain stress system.

Within the addiction process, the concept of motivation is linked to hedonic, affective, and emotional states in the context of temporal dynamics that are elaborated by Solomon's opponent process theory of motivation.[11] Hedonic, affective, or emotional states, once initiated, are modulated by the central nervous system with mechanisms that reduce the intensity of hedonic feelings. This theory postulates that any motivational stimulus activates two opposing motivational processes. The *a-process* consists of positive or negative hedonic responses, has a fast onset and offset, correlates with the intensity, quality, and duration of the stimulus, and shows tolerance. The *b-process* appears after the *a-process* has terminated, is opposite in direction, is sluggish in onset, is slow to build up and decay, and gets larger with repeated exposure. The initial acute effect of a drug of abuse (ie, the *a-process* or positive hedonic response) was hypothesized to be opposed or counteracted by the *b-process* as homeostatic changes in brain systems. With repeated exposure to drugs, the *b-process* sensitizes, appears earlier after the unconditioned stimulus, lasts longer, and masks the *a-process*, leading to apparent tolerance.[12] Two types of biological processes have been proposed to describe the mechanisms that underlie the neuroadaptations that are associated with generation of the opponent process in drug addiction: within-system adaptation and between-system adaptation.[13] In the within-system process, the drug elicits an opposing, neutralizing reaction within the same system in which the drug elicits its primary and unconditioned reinforcing actions. In the between-system process, neurobiological systems are recruited that are different from the ones that were initially activated by the drug.

Neurobiological mechanisms of drug addiction

Binge/intoxication stage

Intense research efforts over the past three decades have been dedicated to revealing the neurochemical

elements and neuronal networks that are responsible for the *binge/intoxication* stage (*Figure 3*).[14] Converging evidence suggests that three main contributors to the *binge/intoxication* stage in the early stages of drug addiction are (i) the acute positive hedonic value of drugs,[15] (ii) sensitization of incentive salience,[16] and (iii) inherent poor cognitive insight.[17] The later stages of drug addiction also exhibit a *binge/intoxication* stage that also includes tolerance and is fueled by the negative emotional states that are an important driving force to the maintenance of chronic and heavy drug use.

Intoxicating doses of drugs, including alcohol, produce the release of dopamine and endogenous opioids in the ventral striatum that correlate with the subjective effects of drugs, including feelings of being "high."[18,19] Earlier preclinical work showed that all drugs of abuse increase dopamine release in the ventral striatum, leading to theories that suggested that this increase may be related to the hedonic value of drugs of abuse.[15] Moreover, dopamine plays a key role in psychostimulant reward, but dopamine-independent reward has also been demonstrated for opioids and alcohol.[20-22] Further work established a key common role for dopamine in addiction. The dopaminergic system is important within a subcomponent of motivational systems that allows the attribution of incentive salience. Incentive salience (anchored within the construct of conditioned reinforcement) is a phenomenon by which a previously neutral stimulus acquires incentive value through pairing with a drug of abuse.[16] Robust evidence indicates that dopamine plays a minor role, if any, in reward processing per se and may represent instead a reward prediction error signal.[23]

The theory of sensitization of incentive salience has its origins in early work on conditioned reinforcement.[24] Prominent work has shown that dopamine neurons are crucial for mediating such conditioned reinforcement. Dopamine neurons in the ventral tegmental area and substantia nigra have been shown to exhibit phasic responding to a nonpredicted reward. After repeated exposure, the same neurons stop responding to a predictable reward and instead start responding to the earliest cue that predicts the future reward.[25,26] This process allows neutral cues to acquire incentive salience and thus elicit behavioral approach. One hypothesis is that the progressive sensitization of this phasic responding to cues that is associated with drug reward may contribute to maladaptive craving that is observed in individuals with substance-use disorders,[27,28] although clinical

evidence for such a phenomenon is sparse.[29] Preclinical evidence indicates that drugs of abuse can produce a shift in the excitatory balance of dopamine neurons after acute administration,[30-38] suggesting that neuroadaptations in the dopamine incentive salience system can occur early in the addiction process. Moreover, a recent study in humans showed that the phenomenon of conditioned responding of dopamine neurons to drug-predictive cues occurred in recreational cocaine users who did not meet the criteria for cocaine-use disorders.[39] These results suggest that the phenomenon of sensitization of incentive salience may be important early in the addiction process but may not be a key mechanism in later stages of addiction. In contrast, there is converging evidence in the preclinical literature that the later stages of addiction may instead involve a transition from goal-directed behavior that is mediated by the ventral striatum to habit behavior that is under the control of the dorsal striatum and that is facilitated by chronic exposure to the drug.[40-49]

Preclinical work has shown that the activation of dopamine D_1 but not D_2 receptors,[50,51] μ-opioid receptors (MORs),[52] nociceptin opioid (NOP) receptors,[53] and α4-, β2-, and α6-containing nicotinic acetylcholine receptors (nAChRs) are required for the acute rewarding and reinforcing effects of drugs. However, these requirements are usually specific to the particular drug of abuse (D_1 for cocaine, MOR for opioids, and nAChRs for nicotine). The only exception may be NOP receptors, which have recently been shown to affect cocaine, heroin, and alcohol self-administration and drug-induced conditioned place preference.[53] Other neurotransmitter systems, including the serotonin 5-hydroxytryptamine (5-HT),[54,55] γ-aminobutyric acid (GABA),[55] acetylcholinergic (ACh),[55] and endocannabinoid[35,56-59] systems, are believed to contribute to the *binge/intoxication* stage by modulating dopamine, opioid, and nicotinic systems, although a more central role for the GABA system has been identified in the mediation of the intoxicating and reinforcing effects of alcohol.[60]

Withdrawal/negative affect stage

Our understanding of the neurobiology of the *withdrawal/negative affect* stage has dramatically increased in the past decade. This stage includes different sources of motivation to take drugs, including chronic irritability, emotional pain, malaise, dysphoria, alexithymia (in-

ability to identify/express emotions), states of stress, and the loss of motivation for natural rewards. For example, chronic administration of all major drugs of abuse leads to stress and anxiety-like responses during acute and protracted abstinence.[61]

One explanation for the blunted function of the reward system during abstinence involves within-system neuroadaptations, in which the primary target of the drug rapidly adapts to neutralize the effect of the drug. Long-lasting within-system adaptations can then lead to a decrease in brain reward function when the drug is removed.[13] For example, cocaine acutely produces dopamine and serotonin release, but decreases in dopaminergic and serotonergic transmission have been observed in the ventral striatum during cocaine withdrawal in rats.[62] Even more compelling are studies in humans that reported lower self-reported rewarding effects of drugs and a lower striatal dopamine response after amphetamine/methylphenidate challenges in active and detoxified abusers than in controls.[63-66] Similar neuroadaptations are hypothesized to occur for other classes of drugs, including increases in MOR responsivity during opioid withdrawal,[67,68] decreases in GABAergic transmission in the ventral striatum, and increases in N-methyl-D-aspartate glutamatergic transmission in the ventral striatum.[69,70] Complex regional changes in function in key brain regions, including the ventral tegmental area, ventral striatum, interpeduncular nucleus (IPN), amygdala, and habenula, have been reported for nicotine and alcohol addiction, among other addictions.[71,72] Such within-system neuroadaptations may contribute to the *withdrawal/negative affect stage* by decreasing brain reward function during abstinence but may also be involved in the *preoccupation/anticipation* stage by providing a greater hedonic driving force to resume drug use.

Another explanation for the lower function of the reward system during abstinence involves between-system neuroadaptations, in which systems other than those that are involved in the positive rewarding effects of drugs are recruited or dysregulated by chronic drug use to oppose the rewarding effects of drugs of abuse.[13] A central component of this between-system neuroadaptation is activation of the stress pathways, including the hypothalamic-pituitary-adrenal (HPA) axis and extrahypothalamic brain stress systems that are mediated by corticotropin-releasing factor (CRF), norepinephrine, and dynorphin.[73-75] Withdrawal from drugs of abuse acutely increases adrenocorticotropic hormone, corticosterone, and extended amygdala CRF and dynorphin during withdrawal.[76-83]

Two main brain circuits probably contribute to these opponent-like processes that lower brain reward function and increase brain stress system function. Both of these circuits are heavy influenced by CRF. One circuit involves the extended amygdala, which encompasses the central nucleus of the amygdala (CeA), bed nucleus of the stria terminalis (BNST), and part of the nucleus accumbens (*Figure 3*). The extended amygdala integrates brain arousal-stress and reward system information[84] to produce the between-system opponent process that is elaborated above. The CRF system in the extended amygdala is activated during acute withdrawal from cocaine, alcohol, opioids, Δ^9-tetrahydrocannabinol, and nicotine.[78,85,86] Similar effects have been observed with alcohol in the lateral BNST.[81] Cocaine withdrawal produces anxiety-like responses that can be reversed by a CRF-receptor antagonist.[87,88] Similar results have been observed with nicotine,[86,89,90] alcohol,[79,91] and opioids.[88,92,93] Moreover, the ability of CRF receptor antagonists to block the anxiogenic-like and aversive-like motivational effects of drug withdrawal predicts the efficacy in reducing compulsive-like self-administration of cocaine,[94] nicotine,[86] and heroin[95] in rats. Although very promising, the clinical development of CRF_1-receptor antagonists for the treatment of drug- and alcohol-use disorders has mostly failed.[96,97] However, these failures should be considered cautiously because the compounds that have been used have less than ideal pharmacokinetics/pharmacodynamics and physicochemical properties, and several other shortcomings in these studies may explain their negative outcomes (for details, see Spierling and Zorrilla[98]).

The excessive release of dopamine and opioid peptides produces subsequent activation of the dynorphin system in the basal ganglia and extended amygdala, which has been hypothesized to feed back to decrease dopamine release and contribute to the dysphoric syndrome that is associated with cocaine dependence.[99] Dynorphins produce aversive dysphoric-like effects in animals and humans and have been hypothesized to mediate negative emotional states[100,101] and depression-like, aversive responses to stress and dysphoric-like responses during withdrawal from drugs of abuse. Recent evidence suggests that the dynorphin/κ-opioid system in the extended amygdala also mediates compulsive-

like responding for methamphetamine, heroin, and alcohol with extended access and dependence.[101]

Another system is the habenula-to-IPN pathway. The habenula plays a key role in encoding aversive states,[102,103] in part by decreasing dopamine neuron firing in the ventral tegmental area after failure to receive an expected reward.[102,103] This hypothesis is consistent with the finding that nAChRs in the habenula-IPN appear to modulate aversive responses to nicotine[104] and nicotine withdrawal.[105,106] We recently reported that the habenula-IPN pathway is also under the influence of the CRF system.[90,106] Activation of this pathway during nicotine withdrawal was potentiated by CRF-producing neurons in the ventral tegmental area that project to the IPN. The downregulation of CRF messenger RNA in the ventral tegmental area and CRF_1-receptor blockade in the IPN prevented emergence of the negative emotional states associated with withdrawal and reduced excessive nicotine intake after abstinence.[90,106]

In addition to these subcortical circuits that involve the brain reward and stress systems, the insular cortex is an important cortical region for emotional aspects of the *withdrawal/negative affect* stage. Cravings for food, cocaine, and nicotine have been shown to activate the insular cortex,[107-109] and tobacco smokers with damage to the insular cortex were able to stop smoking easily with little, if any, withdrawal symptoms, craving, or relapse.[110] The insula is hypothesized to integrate autonomic, visceral, and emotional information[111] during withdrawal and abstinence to produce the motivation to obtain the drug within a negative reinforcement framework (ie, obtain relief from negative emotional states associated with withdrawal). Supporting this hypothesis, imaging studies have reported differential activation of the insula during craving, possibly reflecting interoceptive cues. Such activation during craving also could be driven by the activation of cortical CRF systems when considering the substantial level of CRF neurons and CRF_1 receptors in the insula.[112,113] Finally, reactivity of the insular cortex has been suggested to serve as a biomarker to help predict relapse.[114]

Preoccupation/anticipation stage

Intoxicating doses of drugs, particularly alcohol, marijuana, and opioids, and high doses of psychostimulants are associated with cognitive impairments, including poor working memory, inattention, impulsivity, and delay discounting[115] (for review, see Oscar-Berman and Hutner[116]). Such cognitive impairment significantly contributes to relapse and the escalation of drug intake and results from drug-induced dysfunction of the dorsolateral, ventrolateral, and lateral prefrontal cortex and orbitofrontal cortex (*Figure 3*).[115,117-120] For example, working-memory impairments have been associated with higher levels of alcohol, methamphetamine, and cocaine use in both humans and rats.[121-125]

Craving is a key part of the *preoccupation/anticipation* stage. Large interindividual variability has been observed in the intensity of craving and the source of craving. In humans, cue-induced craving activates the dorsolateral prefrontal cortex, anterior cingulate gyrus, and medial orbitofrontal cortex.[126-130] Cues that are associated with cocaine craving also increase do-

Figure 3. (Opposite) Neural circuitry associated with the three stages of the addiction cycle. (**A**) *Binge/intoxication* stage. Reinforcing effects of drugs may engage associative mechanisms and reward neurotransmitters in the nucleus accumbens shell and core and then engage stimulus-response habits that depend on the dorsal striatum. Two major neurotransmitters that mediate the rewarding effects of drugs of abuse are dopamine and opioid peptides. (**B**) *Withdrawal/negative affect* stage. The negative emotional state of withdrawal may engage the activation of the extended amygdala. The extended amygdala is composed of several basal forebrain structures, including the bed nucleus of the stria terminalis, central nucleus of the amygdala, and possibly a transition area in the medial portion (or shell) of the nucleus accumbens. Major neurotransmitters in the extended amygdala that are hypothesized to play a role in negative reinforcement are corticotropin-releasing factor, norepinephrine, and dynorphin. The extended amygdala has major projections to the hypothalamus and brain stem. (**C**) *Preoccupation/anticipation* (craving) stage. This stage involves the processing of conditioned reinforcement in the basolateral amygdala and processing of contextual information in the hippocampus. Executive control depends on the prefrontal cortex and includes the representation of contingencies, the representation of outcomes, their value, and subjective states (ie, craving and, presumably, feelings) associated with drugs. The subjective effects, termed drug craving in humans, involves activation of the orbitofrontal and anterior cingulate cortex and temporal lobe, including the amygdala, in functional imaging studies. A major neurotransmitter that is involved in the craving stage is glutamate that is localized in pathways from frontal regions and the basolateral amygdala that project to the ventral striatum. ACC, anterior cingulate cortex; BNST, bed nucleus of the stria terminalis; CeA, central nucleus of the amygdala; CRF, corticotropin-releasing factor; dlPFC, dorsolateral prefrontal cortex; DS, dorsal striatum; GABA, γ-aminobutyric acid; GP, globus pallidus; HPC, hippocampus; NAc, nucleus accumbens; OFC, orbitofrontal cortex; Thal, thalamus; vlPFC, ventrolateral prefrontal cortex; vmPFC, ventromedial prefrontal cortex.
Modified with permission from reference 14: Koob GF, Everitt BJ, Robbins TW. Reward, motivation, and addiction. In: Squire LG, Berg D, Bloom FE, Du Lac S, Ghosh A, Spitzer N, eds. *Fundamental Neuroscience*. 3rd edition. Amsterdam, the Netherlands: Academic Press; 2008:987-1016. Copyright © Academic Press, 2008

pamine release in the ventral striatum, prefrontal cortex, and amygdala and endogenous opioid peptide release in the frontal cortex and anterior cingulate.[131-134] Such activation of the reward/salience systems during acute craving episodes is further potentiated because of a decrease in the inhibitory function of the prefrontal cortex (orbitofrontal cortex, ventromedial cortex, and anterior cingulate cortex) in humans with substance-use disorders.[19,135,136] Indeed, substance-use disorder is associated with chronic executive dysfunction, including impairments in decision making, self-regulation, inhibitory control, attention, and working memory,[117] that may be caused by increases in GABAergic and CRF activity in the prefrontal cortex.[123,137] Another key neurotransmitter system that is associated with impairments in behavioral inhibition is the dopaminergic system. Brain imaging has consistently shown lower dopamine D_2 receptor availability in the striatum and prefrontal cortex after protracted abstinence in humans, nonhuman primates, and rodents.[138] Preclinical models have shown that lower D_2 receptor availability is associated with greater motivation for cocaine[139] and cognitive deficits.[140] Decreases in striatal dopamine, combined with increases in GABA and CRF signaling in the prefrontal cortex, may lead to an overactive "Go" system that drives craving and habits and a hypoactive "Stop" system that normally inhibits impulsive behavior and negative emotional states through the activation of specific corticostriatal loops.[141-144]

Implications for personalized medicine

Our thesis is that there are considerable individual differences in the patterns of drug use and the psychological mechanisms that drive drug use. Drug use may be driven by the *binge/intoxication* stage for some individuals and by the *withdrawal/negative affect* stage for others. With psychostimulants and even alcohol, binge-like patterns can predominate in some individuals. Such individuals may escalate their drug intake in a binge-like pattern for various reasons, including peer pressure, sensation seeking, externalizing disorders, and drug-induced cognitive impairment (eg, decision making, monitoring, renegade attention, and transcendence failure) with little, if any, initial negative emotional symptoms. Other individuals may quickly develop a pattern of chronic and heavy use that is caused by either conscious or unconscious attempts to self-medicate existing negative emotional states. Such individuals often have preexisting conditions that generate powerful negative emotional states, such as posttraumatic stress disorders, sexual abuse, major depressive disorder, or anxiety disorder, and will use drugs to obtain relief from these negative emotional states. However, chronic high-dose binge-like patterns of drug intake can cause the development of negative emotional states and ultimately drive self-medication of a state that is created by the drug itself. Ultimately, both the *binge/intoxication* stage and *withdrawal/negative affect* stage will contribute to a pathological state of compulsive drug seeking and taking. One intriguing area of research is the identification of genetic, biological, and psychological subpopulations of humans with substance-use disorder within the framework of the three stages of addiction to better understand the drug addiction process and potentially predict treatment efficacy. Our thesis is that addiction treatments may benefit from the development of medications that specifically target each phase of the addiction process to personalize treatment and obtain better treatment outcome and compliance. In the past decade, notable advances have been made, and there is clear clinical evidence in humans that some treatments (eg, naltrexone) may be better suited for the treatment of the *binge/intoxication* stage, whereas others (eg, acamprosate) may be more appropriate for the *preoccupation/anticipation* stage. However, to date, these findings have had little impact in real life for the treatment of substance-use disorders because of the limited number of available medications and limited number of patients who receive appropriate treatment.

There are individual differences in executive function, prefrontal cortex function, brain stress system function, and dopamine reward signaling, and the genetics of negative emotional states may help identify subgroups of patients with substance-use disorder that may help predict treatment outcome. Attempts are being made to identify genetic markers, including single-nucleotide polymorphisms (SNPs), that may predict the vulnerability to substance-use disorders and responsiveness to treatment. Several research groups have identified gene variants in the metabolic enzymes and receptors that are directly modulated by drugs of abuse, such as MOR, nAChRs, cytochrome p450, and alcohol dehydrogenase. Such findings are very encouraging and suggest that some of these gene variants may predict the response to specific treatments.[145-149] Several SNPs that are associated with the CRF system have also been associated with excessive alcohol use. An association was found between SNPs that are related to the CRF_1 receptor gene (*Crhr1*) and binge drink-

ing in adolescents and alcohol-dependent adults.[150-152] Another important genetic association has been found between alcohol dependence and SNPs that are related to the gene that encodes neuropeptide Y (NPY). NPY is an anxiolytic peptide that is involved in emotional regulation and stress coping and is known to antagonize the effects of CRF on addiction-like behaviors. Studies have linked SNPs of the Y_2 receptor gene (*NPY2R*) and alcohol dependence, alcohol withdrawal symptoms, comorbid alcohol and cocaine dependence, and cocaine dependence.[153] The G1258A polymorphism of the NPY gene has been linked to alcohol dependence.[154] The rs16147 SNP of the NPY promoter gene was linked to tobacco addiction.[155] Should a medication become available that modulates CRF or NPY, such genetic analysis may reveal that subpopulations of subjects who carry specific SNPs might be more responsive than others.

Conclusions

Drug addiction is a chronically relapsing disorder that is associated with compulsive drug seeking and taking that progress through the *binge/intoxication*, *withdrawal/negative affect*, and *preoccupation/anticipation* stages.

These three stages have diverse neurobiological mechanisms that are involved in the transition from recreational to compulsive drug use. We hypothesize that individual differences in the neurobiological systems that underlie the processing of reward, incentive salience, stress, pain, habits, and executive function may explain (i) the vulnerability to developing a substance-use disorder; (ii) the diversity of emotional, motivational, and cognitive profiles of individuals with substance-use disorders; and (iii) the heterogeneous responses to cognitive and pharmacological treatments. We propose that characterization of the neuropsychological mechanisms that underlie individual differences in addiction-like behaviors is a key to understanding the mechanisms of addiction and development of personalized medicine through genomic medicine and personalized pharmacotherapy. ❏

REFERENCES

1. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. *Science.* 1997;278(5335):52-58.
2. Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. *Lancet Psychiatry.* 2016;3(8):760-773.
3. Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. *Neuropsychopharmacology.* 2001;24(2):97-129.
4. Heilig M, Koob GF. A key role for corticotropin-releasing factor in alcohol dependence. *Trends Neurosci.* 2007;30(8):399-406.
5. Koob GF, Le Moal M. Addiction and the brain antireward system. *Annu Rev Psychol.* 2008;59:29-53.
6. Koob GF. Theoretical frameworks and mechanistic aspects of alcohol addiction: alcohol addiction as a reward deficit disorder. *Curr Top Behav Neurosci.* 2013:3-30.
7. Moeller FG, Barratt ES, Dougherty DM, Schmitz JM, Swann AC. Psychiatric aspects of impulsivity. *Am J Psychiatry.* 2001;158(11):1783-1793.
8. Berlin GS, Hollander E. Compulsivity, impulsivity, and the DSM-5 process. *CNS Spectr.* 2014;19(1):62-68.
9. Skinner BF. The Behavior of Organisms: An Experimental Analysis. New York, NY: Apple-Century-Crofts; 1938.
10. Hebb DO. *Textbook of Psychology*, 3rd edition. Philadelphia, PA: WB Saunders; 1972.
11. Solomon RL, Corbit JD. An opponent-process theory of motivation: 1. Temporal dynamics of affect. *Psychol Rev.* 1974;81(2):119-145.
12. Laulin JP, Celerier E, Larcher A, Le Moal M, Simonnet G. Opiate tolerance to daily heroin administration: an apparent phenomenon associated with enhanced pain sensitivity. *Neuroscience.* 1999;89(3):631-636.
13. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. *Science.* 1988;242(4879):715-723.

14. Koob GF, Everitt BJ, Robbins TW. Reward, motivation, and addiction. In: Squire LG, Berg D, Bloom FE, Du Lac S, Ghosh A, Spitzer N, eds. *Fundamental Neuroscience*. 3rd edition. Amsterdam, the Netherlands: Academic Press; 2008:987-1016.
15. Wise RA. The role of reward pathways in the development of drug dependence. *Pharmacol Ther.* 1987;35(1-2):227-263.
16. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. *Brain Res Rev.* 1993;18(3):247-291.
17. Goldstein RZ, Craig AD, Bechara A, et al. The neurocircuitry of impaired insight in drug addiction. *Trends Cogn Sci.* 2009;13(9):372-380.
18. Mitchell JM, O'Neil JP, Janabi M, Marks SM, Jagust WJ, Fields HL. Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens. *Sci Transl Med.* 2012;4(116):116ra116.
19. Volkow ND, Fowler JS, Wang GJ. The addicted human brain: insights from imaging studies. *J Clin Invest.* 2003;111(10):1444-1451.
20. Ettenberg A, Pettit HO, Bloom FE, Koob GF. Heroin and cocaine intravenous self-administration in rats: mediation by separate neural systems. *Psychopharmacology (Berl)* 1982;78(3):204-209.
21. Pettit HO, Ettenberg A, Bloom FE, Koob GF. Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. *Psychopharmacology (Berl).* 1984;84(2):167-173.
22. Rassnick S, Stinus L, Koob GF. The effects of 6-hydroxydopamine lesions of the nucleus accumbens and the mesolimbic dopamine system on oral self-administration of ethanol in the rat. *Brain Res.* 1993;623(1):16-24.
23. Schultz W, Stauffer WR, Lak A. The phasic dopamine signal maturing: from reward via behavioural activation to formal economic utility. *Curr Opin Neurobiol.* 2017;43:139-148.
24. Robbins TW. Relationship between reward-enhancing and stereotypical effects of psychomotor stimulant drugs. *Nature.* 1976;264(5581):57-59.

State of the art

25. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. *Science.* 1997;275(5306):1593-1599.
26. Schultz W. Dopamine reward prediction error coding. *Dialogues Clin Neurosci.* 2016;18(1):23-32.
27. Robinson MJ, Fischer AM, Ahuja A, Lesser EN, Maniates H. Roles of "wanting" and "liking" in motivating behavior: gambling, food, and drug addictions. *Curr Top Behav Neurosci.* 2016;27:105-136.
28. Berridge KC, Robinson TE. Liking, wanting, and the incentive-sensitization theory of addiction. *Am Psychol.* 2016;71(8):670-679.
29. Boileau I, Dagher A, Leyton M, et al. Modeling sensitization to stimulants in humans: an [^{11}C]raclopride/positron emission tomography study in healthy men. *Arch Gen Psychiatry.* 2006;63(12):1386-1395.
30. Ungless MA, Whistler JL, Malenka RC, Bonci A. Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. *Nature.* 2001;411(6837):583-587.
31. Hausknecht K, Shen YL, Wang RX, Haj-Dahmane S, Shen RY. Prenatal ethanol exposure persistently alters endocannabinoid signaling and endocannabinoid-mediated excitatory synaptic plasticity in ventral tegmental area dopamine neurons. *J Neurosci.* 2017;37(24):5798-5808.
32. Bocklisch C, Pascoli V, Wong JC, et al. Cocaine disinhibits dopamine neurons by potentiation of GABA transmission in the ventral tegmental area. *Science.* 2013;341(6153):1521-1525.
33. Mao D, Gallagher K, McGehee DS. Nicotine potentiation of excitatory inputs to ventral tegmental area dopamine neurons. *J Neurosci.* 2011;31(18):6710-6720.
34. Chen BT, Bowers MS, Martin M, et al. Cocaine but not natural reward self-administration nor passive cocaine infusion produces persistent LTP in the VTA. *Neuron.* 2008;59(2):288-297.
35. Pan B, Hillard CJ, Liu QS. Endocannabinoid signaling mediates cocaine-induced inhibitory synaptic plasticity in midbrain dopamine neurons. *J Neurosci.* 2008;28(6):1385-1397.
36. Sarti F, Borgland SL, Kharazia VN, Bonci A. Acute cocaine exposure alters spine density and long-term potentiation in the ventral tegmental area. *Eur J Neurosci.* 2007;26(3):749-756.
37. Melis M, Camarini R, Ungless MA, Bonci A. Long-lasting potentiation of GABAergic synapses in dopamine neurons after a single in vivo ethanol exposure. *J Neurosci.* 2002;22(6):2074-2082.
38. Mansvelder HD, McGehee DS. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. *Neuron.* 2000;27(2):349-357.
39. Cox SM, Yau Y, Larcher K, et al. Cocaine cue-induced dopamine release in recreational cocaine users. *Sci Rep.* 2017;7:46665. doi:10.1038/srep46665.
40. Furlong TM, Corbit LH, Brown RA, Balleine BW. Methamphetamine promotes habitual action and alters the density of striatal glutamate receptor and vesicular proteins in dorsal striatum. *Addict Biol.* 2017 Jul 14. Epub ahead of print. doi:10.1111/adb.12534.
41. Corbit LH, Nie H, Janak PH. Habitual responding for alcohol depends upon both AMPA and D2 receptor signaling in the dorsolateral striatum. *Front Behav Neurosci* 2014;8:301.
42. Palm S, Nylander I. Dopamine release dynamics change during adolescence and after voluntary alcohol intake. *PLoS One.* 2014;9(5):e96337.
43. Fanelli RR, Klein JT, Reese RM, Robinson DL. Dorsomedial and dorsolateral striatum exhibit distinct phasic neuronal activity during alcohol self-administration in rats. *Eur J Neurosci.* 2013;38(4):2637-2648.
44. Corbit LH, Nie H, Janak PH. Habitual alcohol seeking: time course and the contribution of subregions of the dorsal striatum. *Biol Psychiatry.* 2012;72(5):389-395.
45. Belin D, Everitt BJ. Cocaine seeking habits depend upon dopamine-dependent serial connectivity linking the ventral with the dorsal striatum. *Neuron.* 2008;57(3):432-441.
46. Vanderschuren LJ, Di Ciano P, Everitt BJ. Involvement of the dorsal striatum in cue-controlled cocaine seeking. *J Neurosci.* 2005;25(38):8665-8670.
47. Ito R, Dalley JW, Robbins TW, Everitt BJ. Dopamine release in the dorsal striatum during cocaine-seeking behavior under the control of a drug-associated cue. *J Neurosci.* 2002;22(14):6247-6253.
48. Willuhn I, Burgeno LM, Groblewski PA, Phillips PE. Excessive cocaine use results from decreased phasic dopamine signaling in the striatum. *Nat Neurosci.* 2014;17(5):704-709.
49. Willuhn I, Burgeno LM, Everitt BJ, Phillips PE. Hierarchical recruitment of phasic dopamine signaling in the striatum during the progression of cocaine use. *Proc Natl Acad Sci U S A.* 2012;109(50):20703-20708.
50. Caine SB, Thomsen M, Gabriel KI, et al. Lack of self-administration of cocaine in dopamine D1 receptor knock-out mice. *J Neurosci.* 2007;27(48):13140-13150.
51. Caine SB, Negus SS, Mello NK, et al. Role of dopamine D2-like receptors in cocaine self-administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists. *J Neurosci.* 2002;22(7):2977-2988.
52. Roberts AJ, McDonald JS, Heyser CJ, et al. μ-Opioid receptor knockout mice do not self-administer alcohol. *J Pharmacol Exp Ther.* 2000;293(3):1002-1008.
53. Kallupi M, Scuppa G, de Guglielmo G, et al. Genetic deletion of the nociceptin/orphanin FQ receptor in the rat confers resilience to the development of drug addiction. *Neuropsychopharmacology.* 2017;42(3):695-706.
54. Cunningham KA, Anastasio NC. Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction. *Neuropharmacology.* 2014;76(pt B):460-478.
55. Vashchinkina E, Panhelainen A, Aitta-aho T, Korpi ER. GABA$_A$ receptor drugs and neuronal plasticity in reward and aversion: focus on the ventral tegmental area. *Front Pharmacol.* 2014;5:256.
56. Buczynski MW, Herman MA, Hsu KL, et al. Diacylglycerol lipase disinhibits VTA dopamine neurons during chronic nicotine exposure. *Proc Natl Acad Sci U S A.* 2016;113(4):1086-1091.
57. Melis M, Sagheddu C, De Felice M, et al. Enhanced endocannabinoid-mediated modulation of rostromedial tegmental nucleus drive onto dopamine neurons in Sardinian alcohol-preferring rats. *J Neurosci.* 2014;34(38):12716-12724.
58. Rashidy-Pour A, Pahlevani P, Vaziri A, et al. Involvement of CB1 receptors in the ventral tegmental area in the potentiation of morphine rewarding properties in acquisition but not expression in the conditioned place preference model. *Behav Brain Res.* 2013;247:259-267.
59. Malinen H, Hyytiä P. Ethanol self-administration is regulated by CB1 receptors in the nucleus accumbens and ventral tegmental area in alcohol-preferring AA rats. *Alcohol Clin Exp Res.* 2008;32(11):1976-1983.
60. Hyytia P, Koob GF. GABA$_A$ receptor antagonism in the extended amygdala decreases ethanol self-administration in rats. *Eur J Pharmacol.* 1995;283(1-3):151-159.
61. Koob GF, Le Moal M. Plasticity of reward neurocircuitry and the "dark side" of drug addiction. *Nat Neurosci.* 2005;8(11):1442-1444.
62. Weiss F, Markou A, Lorang MT, Koob GF. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. *Brain Res.* 1992;593(2):314-318.
63. Martinez D, Narendran R, Foltin RW, et al. Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. *Am J Psychiatry.* 2007;164(4):622-629.
64. Volkow ND, Wang GJ, Telang F, et al. Profound decreases in dopamine release in striatum in detoxified alcoholics: possible orbitofrontal involvement. *J Neurosci.* 2007;27(46):12700-12706.
65. Volkow ND, Tomasi D, Wang GJ, et al. Stimulant-induced dopamine increases are markedly blunted in active cocaine abusers. *Mol Psychiatry.* 2014;19(9):1037-1043.
66. Volkow ND, Wang GJ, Fowler JS, et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. *Nature.* 1997;386(6627):830-833.
67. Stinus L, Le Moal M, Koob GF. Nucleus accumbens and amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal. *Neuroscience.* 1990;37(3):767-773.
68. Minkowski CP, Epstein D, Frost JJ, Gorelick DA. Differential response to IV carfentanil in chronic cocaine users and healthy controls. *Addict Biol.* 2012;17(1):149-155.
69. Davidson M, Shanley B, Wilce P. Increased NMDA-induced excitability during ethanol withdrawal: a behavioural and histological study. *Brain Res.* 1995;674(1):91-96.
70. Dahchour A, de Witte P, Bolo N, et al. Central effects of acamprosate: Part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. *Psychiatry Res.* 1998;82(2):107-114.

71. Dani JA, Heinemann S. Molecular and cellular aspects of nicotine abuse. *Neuron.* 1996;16(5):905-908.

72. Tolu S, Eddine R, Marti F, et al. Co-activation of VTA DA and GABA neurons mediates nicotine reinforcement. *Mol Psychiatry.* 2013;18(3):382-393.

73. Walker BM, Koob GF. Pharmacological evidence for a motivational role of -opioid systems in ethanol dependence. *Neuropsychopharmacology.* 2008;33(3):643-652.

74. Schlosburg JE, Whitfield TW Jr, Park PE, et al. Long-term antagonism of opioid receptors prevents escalation of and increased motivation for heroin intake. *J Neurosci.* 2013;33(49):19384-19392.

75. Whitfield TW Jr, Schlosburg J, Wee S, et al. Opioid receptors in the nucleus accumbens shell mediate escalation of methamphetamine intake. *J Neurosci.* 2015;35(10):4296-4305.

76. Koob GF, Buck CL, Cohen A, et al. Addiction as a stress surfeit disorder. *Neuropharmacology.* 2014;76(pt B):370-382.

77. Rivier C, Bruhn T, Vale W. Effect of ethanol on the hypothalamic-pituitary-adrenal axis in the rat: role of corticotropin-releasing factor (CRF). *J Pharmacol Exp Ther.* 1984;229(1):127-131.

78. Merlo-Pich E, Lorang M, Yeganeh M, et al. Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. *J Neurosci.* 1995;15(8):5439-5447.

79. Koob GF, Heinrichs SC, Menzaghi F, Pich EM, Britton KT. Corticotropin releasing factor, stress and behavior. *Semin Neurosci.* 1994;6(4):221-229.

80. Rasmussen DD, Boldt BM, Bryant CA, Mitton DR, Larsen SA, Wilkinson CW. Chronic daily ethanol and withdrawal: 1. Long-term changes in the hypothalamo-pituitary-adrenal axis. *Alcohol Clin Exp Res.* 2000;24(12):1836-1849.

81. Olive MF, Koenig HN, Nannini MA, Hodge CW. Elevated extracellular CRF levels in the bed nucleus of the stria terminalis during ethanol withdrawal and reduction by subsequent ethanol intake. *Pharmacol Biochem Behav.* 2002;72(1-2):213-220.

82. Delfs JM, Zhu Y, Druhan JP, Aston-Jones G. Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. *Nature.* 2000;403(6768):430-434.

83. Koob GF. Brain stress systems in the amygdala and addiction. *Brain Res.* 2009;1293:61-75.

84. Heimer L, Alheid G. Piecing together the puzzle of basal forebrain anatomy. In: Napier TC, Kalivas PW, Hanin I, eds. *The Basal Forebrain: Anatomy to Function*. New York, NY: Plenum Press; 1991:1-42. *Advances in Experimental Medicine and Biology*; vol 295.

85. Richter RM, Weiss F. In vivo CRF release in rat amygdala is increased during cocaine withdrawal in self-administering rats. *Synapse.* 1999;32(4):254-261.

86. George O, Ghozland S, Azar MR, et al. CRF-CRF$_1$ system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats. *Proc Natl Acad Sci U S A.* 2007;104(43):17198-17203.

87. Sarnyai Z, Biro E, Gardi J, Vecsernyes M, Julesz J, Telegdy G. Brain corticotropin-releasing factor mediates "anxiety-like" behavior induced by cocaine withdrawal in rats. *Brain Res.* 1995;675(1-2):89-97.

88. Basso AM, Spina M, Rivier J, Vale W, Koob GF. Corticotropin-releasing factor antagonist attenuates the "anxiogenic-like" effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats. *Psychopharmacology (Berl).* 1999;145(1):21-30.

89. Cohen A, Treweek J, Edwards S, et al. Extended access to nicotine leads to a CRF$_1$ receptor dependent increase in anxiety-like behavior and hyperalgesia in rats. *Addict Biol.* 2015;20(1):56-68.

90. Grieder TE, Herman MA, Contet C, et al. VTA CRF neurons mediate the aversive effects of nicotine withdrawal and promote intake escalation. *Nat Neurosci.* 2014;17(12):1751-1758.

91. Rassnick S, Heinrichs SC, Britton KT, Koob GF. Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. *Brain Res.* 1993;605(1):25-32.

92. Heinrichs SC, Menzaghi F, Schulteis G, Koob GF, Stinus L. Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. *Behav Pharmacol.* 1995;6(1):74-80.

93. Schulteis G, Markou A, Gold LH, Stinus L, Koob GF. Relative sensitivity to naloxone of multiple indices of opiate withdrawal: a quantitative dose-response analysis. *J Pharmacol Exp Ther.* 1994;271(3):1391-1398.

94. Goeders NE, Guerin GF. Effects of the CRH receptor antagonist CP-154,526 on intravenous cocaine self-administration in rats. *Neuropsychopharmacology.* 2000;23(5):577-586.

95. Greenwell TN, Funk CK, Cottone P, et al. Corticotropin-releasing factor-1 receptor antagonists decrease heroin self-administration in long-, but not short-access rats. *Addict Biol.* 2009;14(2):130-143.

96. Kwako LE, Spagnolo PA, Schwandt ML, et al. The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study. *Neuropsychopharmacology* 2015;40(5):1053-1063.

97. Schwandt ML, Cortes CR, Kwako LE, et al. The CRF1 antagonist verucerfont in anxious alcohol-dependent women: translation of neuroendocrine, but not of anti-craving effects. *Neuropsychopharmacology.* 2016;41(12):2818-2829.

98. Spierling SR, Zorrilla EP. Don't stress about CRF: assessing the translational failures of CRF$_1$ antagonists. *Psychopharmacology (Berl).* 2017;234(9-10):1467-1481.

99. Carlezon WA Jr, Nestler EJ, Neve RL. Herpes simplex virus-mediated gene transfer as a tool for neuropsychiatric research. *Crit Rev Neurobiol.* 2000;14(1):47-67.

100. Koob GF. The dark side of emotion: the addiction perspective. *Eur J Pharmacol.* 2015;753:73-87.

101. Chavkin C, Koob GF. Dynorphin, dysphoria and dependence: the stress of addiction. *Neuropsychopharmacology.* 2016;41(1):373-374.

102. Hikosaka O. The habenula: from stress evasion to value-based decision-making. *Nat Rev Neurosci.* 2010;11(7):503-513.

103. Matsumoto M, Hikosaka O. Lateral habenula as a source of negative reward signals in dopamine neurons. *Nature.* 2007;447(7148):1111-1115.

104. Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ. Habenular 5 nicotinic receptor subunit signalling controls nicotine intake. *Nature.* 2011;471(7340):597-601.

105. Salas R, Sturm R, Boulter J, De Biasi M. Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice. *J Neurosci.* 2009;29(10):3014-3018.

106. Zhao-Shea R, DeGroot SR, Liu L, et al. Increased CRF signalling in a ventral tegmental area-interpeduncular nucleus-medial habenula circuit induces anxiety during nicotine withdrawal. *Nat Commun.* 2015;6:6770.

107. Bonson KR, Grant SJ, Contoreggi CS, et al. Neural systems and cue-induced cocaine craving. *Neuropsychopharmacology.* 2002;26(3):376-386.

108. Pelchat ML, Johnson A, Chan R, Valdez J, Ragland JD. Images of desire: food-craving activation during fMRI. *Neuroimage.* 2004;23(4):1486-1493.

109. Wang Z, Faith M, Patterson F, et al. Neural substrates of abstinence-induced cigarette cravings in chronic smokers. *J Neurosci.* 2007;27(51):14035-14040.

110. Naqvi NH, Rudrauf D, Damasio H, Bechara A. Damage to the insula disrupts addiction to cigarette smoking. *Science.* 2007;315(5811):531-534.

111. Naqvi NH, Bechara A. The hidden island of addiction: the insula. *Trends Neurosci.* 2009;32(1):56-67.

112. Sanchez MM, Young LJ, Plotsky PM, Insel TR. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. *J Comp Neurol.* 1999;408(3):365-377.

113. Goudriaan AE, De Ruiter MB, van den Brink W, Oosterlaan J, Veltman DJ. Brain activation patterns associated with cue reactivity and craving in abstinent problem gamblers, heavy smokers and healthy controls: an fMRI study. *Addict Biol.* 2010;15(4):491-503.

114. Janes AC, Pizzagalli DA, Richardt S, et al. Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence. *Biol Psychiatry.* 2010;67(8):722-729.

115. Jentsch JD, Taylor JR. Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. *Psychopharmacology.* 1999;146(4):373-390.

116. Oscar-Berman M, Hutner N. Frontal lobe changes after chronic alcohol ingestion. In: Hunt WA, Nixon SJ, eds. *Alcohol-Induced Brain Damage*. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 1993:121-156. *NIAAA Research Monograph*; vol 22.

117. Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F. Addiction: beyond dopamine reward circuitry. *Proc Natl Acad Sci U S A.* 2011;108(37):15037-15042.

118. Baldacchino A, Balfour DJ, Passetti F, Humphris G, Matthews K. Neuropsychological consequences of chronic opioid use: a quantitative review and meta-analysis. *Neurosci Biobehav Rev.* 2012;36(9):2056-2068.

119. London ED, Kohno M, Morales AM, Ballard ME. Chronic methamphetamine abuse and corticostriatal deficits revealed by neuroimaging. *Brain Res.* 2015;1628(pt A):174-185.

120. Robbins TW, Ersche KD, Everitt BJ. Drug addiction and the memory systems of the brain. *Ann N Y Acad Sci.* 2008;1141:1-21.

121. George O, Koob GF. Individual differences in prefrontal cortex function and the transition from drug use to drug dependence. *Neurosci Biobehav Rev.* 2010;35(2):232-247.

122. George O, Mandyam CD, Wee S, Koob GF. Extended access to cocaine self-administration produces long-lasting prefrontal cortex-dependent working memory impairments. *Neuropsychopharmacology.* 2008;33(10):2474-2482.

123. George O, Sanders C, Freiling J, et al. Recruitment of medial prefrontal cortex neurons during alcohol withdrawal predicts cognitive impairment and excessive alcohol drinking. *Proc Natl Acad Sci U S A.* 2012;109(44):18156-18161.

124. Recinto P, Samant AR, Chavez G, et al. Levels of neural progenitors in the hippocampus predict memory impairment and relapse to drug seeking as a function of excessive methamphetamine self-administration. *Neuropsychopharmacology.* 2012;37(5):1275-1287.

125. Briand LA, Flagel SB, Seeman P, Robinson TE. Cocaine self-administration produces a persistent increase in dopamine D_2^{High} receptors. *Eur Neuropsychopharmacol.* 2008;18(8):551-556.

126. Kober H, Lacadie CM, Wexler BE, Malison RT, Sinha R, Potenza MN. Brain activity during cocaine craving and gambling urges: an fMRI study. *Neuropsychopharmacology.* 2016;41(2):628-637.

127. Lee JH, Lim Y, Wiederhold BK, Graham SJ. A functional magnetic resonance imaging (fMRI) study of cue-induced smoking craving in virtual environments. *Appl Psychophysiol Biofeedback.* 2005;30:195-204.

128. Risinger RC, Salmeron BJ, Ross TJ, et al. Neural correlates of high and craving during cocaine self-administration using BOLD fMRI. *Neuroimage* 2005;26(3):1097-1108.

129. Volkow ND, Wang GJ, Ma Y, et al. Activation of orbital and medial prefrontal cortex by methylphenidate in cocaine-addicted subjects but not in controls: relevance to addiction. *J Neurosci.* 2005;25(15):3932-3939.

130. Jasinska AJ, Stein EA, Kaiser J, Naumer MJ, Yalachkov Y. Factors modulating neural reactivity to drug cues in addiction: a survey of human neuroimaging studies. *Neurosci Biobehav Rev.* 2014;38:1-16.

131. Fotros A, Casey KF, Larcher K, et al. Cocaine cue-induced dopamine release in the amygdala and hippocampus: a high-resolution PET [^{18}F]fallypride study in cocaine dependent participants. *Neuropsychopharmacology.* 2013;38(9):1780-1788.

132. Volkow ND, Wang GJ, Telang F, et al. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. *J Neurosci.* 2006;26(24):6583-6588.

133. Milella MS, Fotros A, Gravel P, et al. Cocaine cue-induced dopamine release in the human prefrontal cortex. *J Psychiatry Neurosci.* 2016;41(5):322-330.

134. Koob GF, Volkow ND. Neurocircuitry of addiction. *Neuropsychopharmacology.* 2010;35:217-238. [Erratum published in *Neuropsychopharmacology.* 2010;35(4):1051].

135. Volkow ND, Wang GJ, Fowler JS, et al. Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. *Am J Psychiatry.* 1999;156(1):19-26.

136. Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. *Nat Rev Neurosci* 2011;12(11):652-669.

137. Bryce CA, Floresco SB. Perturbations in effort-related decision-making driven by acute stress and corticotropin-releasing factor. *Neuropsychopharmacology.* 2016;41(8):2147-2159.

138. Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F. Imaging dopamine's role in drug abuse and addiction. *Neuropharmacology.* 2009;56(suppl 1):3-8.

139. Thanos PK, Michaelides M, Umegaki H, Volkow ND. D2R DNA transfer into the nucleus accumbens attenuates cocaine self-administration in rats. *Synapse.* 2008;62(7):481-486.

140. Groman SM, Lee B, Seu E, et al. Dysregulation of D_2-mediated dopamine transmission in monkeys after chronic escalating methamphetamine exposure. *J Neurosci.* 2012;32(17):5843-5852.

141. Lobo MK, Nestler EJ. The striatal balancing act in drug addiction: distinct roles of direct and indirect pathway medium spiny neurons. *Front Neuroanat.* 2011;5:41.

142. Volkow ND, Morales M. The brain on drugs: from reward to addiction. *Cell.* 2015;162(4):712-725.

143. Bechara A, Damasio H, Damasio AR, Lee GP. Different contributions of the human amygdala and ventromedial prefrontal cortex to decision-making. *J Neurosci.* 1999;19(13):5473-5481.

144. Johnstone T, van Reekum CM, Urry HL, Kalin NH, Davidson RJ. Failure to regulate: counterproductive recruitment of top-down prefrontal-subcortical circuitry in major depression. *J Neurosci.* 2007;27(33):8877-8884.

145. Clarke TK, Crist RC, Kampman KM, et al. Low frequency genetic variants in the μ-opioid receptor (*OPRM1*) affect risk for addiction to heroin and cocaine. *Neurosci Lett.* 2013;542:71-75.

146. Wachman EM, Hayes MJ, Brown MS, et al. Association of *OPRM1* and *COMT* single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. *JAMA.* 2013;309(17):1821-1827.

147. Thorgeirsson TE, Gudbjartsson DF, Surakka I, et al; ENGAGE Consortium. Sequence variants at *CHRNB3-CHRNA6* and *CYP2A6* affect smoking behavior. *Nat Genet.* 2010;42(5):448-453.

148. Levran O, O'Hara K, Peles E, et al. *ABCB1* (*MDR1*) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. *Hum Mol Genet.* 2008;17(14):2219-2227.

149. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. *Nature.* 2008;452(7187):638-642.

150. Chen AC, Manz N, Tang Y, et al. Single-nucleotide polymorphisms in corticotropin releasing hormone receptor 1 gene (*CRHR1*) are associated with quantitative trait of event-related potential and alcohol dependence. *Alcohol Clin Exp Res.* 2010;34(6):988-996.

151. Schmid B, Blomeyer D, Treutlein J, et al. Interacting effects of *CRHR1* gene and stressful life events on drinking initiation and progression among 19-year-olds. *Int J Neuropsychopharmacol* .2010;13(6):703-714.

152. Treutlein J, Kissling C, Frank J, et al. Genetic association of the human corticotropin releasing hormone receptor 1 (*CRHR1*) with binge drinking and alcohol intake patterns in two independent samples. *Mol Psychiatry.* 2006;11(6):594-602.

153. Wetherill L, Schuckit MA, Hesselbrock V, et al. Neuropeptide Y receptor genes are associated with alcohol dependence, alcohol withdrawal phenotypes, and cocaine dependence. *Alcohol Clin Exp Res.* 2008;32(12):2031-2040.

154. Bhaskar LV, Thangaraj K, Kumar KP, Pardhasaradhi G, Singh L, Rao VR. Association between neuropeptide Y gene polymorphisms and alcohol dependence: a case-control study in two independent populations. *Eur Addict Res.* 2013;19(6):307-313.

155. Mutschler J, Abbruzzese E, von der Goltz C, et al. Genetic variation in the neuropeptide Y gene promoter is associated with increased risk of tobacco smoking. *Eur Addict Res.* 2012;18(5):246-252.

Diferencias individuales en la neuropsicopatología de la adicción

La adicción a drogas o el trastorno por uso de sustancias es un trastorno crónico con recaídas que progresa a través de las etapas de compulsión / intoxicación, abstinencia/afecto negativo y preocupación/anticipación. Estas etapas representan diversos mecanismos neurobiológicos que participan diferenciadamente en la transición desde el uso recreacional al uso compulsivo de la droga y desde un refuerzo positivo a uno negativo. La progresión, desde un uso recreacional de la sustancia a uno compulsivo, está asociada con una regulación negativa de los sistemas cerebrales de recompensa y una regulación positiva de los sistemas cerebrales del estrés. Las diferencias individuales en los sistemas neurobiológicos que están a la base del procesamiento de la recompensa, del aumento del incentivo, de los hábitos, del estrés, del dolor, y de la función ejecutiva pueden explicar: 1) la vulnerabilidad al trastorno por uso de sustancias, 2) la diversidad de los perfiles emocionales, motivacionales y cognitivos de los sujetos con trastornos por uso de sustancias y 3) las respuestas heterogéneas a los tratamientos cognitivos y farmacológicos. La clave para comprender los mecanismos de la adicción y el desarrollo de una farmacoterapia personalizada es la caracterización de los mecanismos neuropsicológicos que subyacen a las diferencias individuales en las conductas adictivas.

Différences individuelles dans la neuro-psycho-pathologie de l'addiction

L'addiction aux drogues ou le trouble de l'usage d'une substance est une maladie à rechutes chroniques qui évolue par des étapes de compulsion/intoxication, sevrage/effet négatif et préoccupation/anticipation. Ces étapes représentent des mécanismes neurobiologiques variés différemment impliqués dans la transition allant de l'usage récréatif à l'usage compulsif d'une drogue et du renforcement positif au renforcement négatif. Le passage de l'usage récréatif à l'usage compulsif d'une substance est associé à une régulation négative des systèmes cérébraux de récompense et à une régulation positive des systèmes cérébraux de stress. Des différences individuelles dans les systèmes neurobiologiques sous-tendant le processus de récompense, de saillance incitative, d'habitudes, de stress, de douleur et de fonction exécutive peuvent expliquer 1) la vulnérabilité aux troubles liés à l'usage de substances ; 2) la diversité des profils émotionnels, motivationnels et cognitifs des individus souffrant de troubles liés à l'usage de substances et 3) les réponses hétérogènes aux traitements cognitifs et pharmacologiques. La clé de la compréhension des mécanismes d'addiction et du développement de traitements pharmacologiques personnalisés est la caractérisation des mécanismes neuropsychologiques sous-tendant les différences individuelles dans les comportements addictifs.